Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
33.29
-0.39 (-1.16%)
Dec 20, 2024, 4:00 PM EST - Market closed
Exelixis Employees
Exelixis had 1,310 employees as of December 31, 2023. The number of employees increased by 87 or 7.11% compared to the previous year.
Employees
1,310
Change (1Y)
87
Growth (1Y)
7.11%
Revenue / Employee
$1,589,006
Profits / Employee
$356,431
Market Cap
9.51B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,310 | 87 | 7.11% |
Dec 31, 2022 | 1,223 | 269 | 28.20% |
Dec 31, 2021 | 954 | 181 | 23.42% |
Dec 31, 2020 | 773 | 156 | 25.28% |
Dec 31, 2019 | 617 | 133 | 27.48% |
Dec 31, 2018 | 484 | 112 | 30.11% |
Dec 31, 2017 | 372 | 85 | 29.62% |
Dec 31, 2016 | 287 | 172 | 149.57% |
Dec 31, 2015 | 115 | 17 | 17.35% |
Dec 31, 2014 | 98 | -129 | -56.83% |
Dec 31, 2013 | 227 | 53 | 30.46% |
Dec 31, 2012 | 174 | -26 | -13.00% |
Dec 31, 2011 | 200 | -183 | -47.78% |
Dec 31, 2010 | 383 | -293 | -43.34% |
Dec 31, 2009 | 676 | 0 | - |
Dec 31, 2008 | 676 | -59 | -8.03% |
Dec 31, 2007 | 735 | 84 | 12.90% |
Dec 31, 2006 | 651 | 101 | 18.36% |
Dec 31, 2005 | 550 | 33 | 6.38% |
Dec 31, 2004 | 517 | -56 | -9.77% |
Dec 31, 2003 | 573 | 23 | 4.18% |
Dec 31, 2002 | 550 | -21 | -3.68% |
Dec 31, 2001 | 571 | 214 | 59.94% |
Dec 31, 2000 | 357 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Encompass Health | 37,761 |
Charles River Laboratories International | 21,800 |
Smith & Nephew | 19,081 |
AptarGroup | 13,800 |
Bio-Rad Laboratories | 8,030 |
Bio-Rad Laboratories | 8,030 |
Qiagen | 5,967 |
Medpace Holdings | 5,900 |
EXEL News
- 24 days ago - Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December - Business Wire
- 25 days ago - Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors - Business Wire
- 6 weeks ago - Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November - Business Wire
- 7 weeks ago - Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine - Seeking Alpha
- 7 weeks ago - Exelixis, Inc. (EXEL) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Business Wire
- 2 months ago - 3 Attractive Biotechs With Recent Positives - Seeking Alpha
- 2 months ago - Exelixis Stays Strong With Cabometyx While New Assets Approach Key Trials - Seeking Alpha